{
    "2019-08-08": [
        [
            {
                "time": "2019-08-08",
                "original_text": "创新药和仿制药仍有较大的机会，这些药企被看好",
                "features": {
                    "keywords": [
                        "创新药",
                        "仿制药",
                        "机会",
                        "药企"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-08-08",
                "original_text": "主力资金近三日都在买这些概念股",
                "features": {
                    "keywords": [
                        "主力资金",
                        "买入",
                        "概念股"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-08-08",
                "original_text": "恒瑞医药10亿级麻醉新药进入优先审评名单",
                "features": {
                    "keywords": [
                        "恒瑞医药",
                        "麻醉新药",
                        "优先审评",
                        "名单"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-08-08",
                "original_text": "医药2019年8月投资月报：政策边际改善，避风港优势再现，维持“推荐”评级",
                "features": {
                    "keywords": [
                        "医药",
                        "投资月报",
                        "政策边际改善",
                        "避风港",
                        "推荐评级"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-08-08",
                "original_text": "政策密集推出 医药生物板块确定性无忧",
                "features": {
                    "keywords": [
                        "政策密集推出",
                        "医药生物板块",
                        "确定性"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}